AFFIMED N V COM EUR0.1 (POST REV SPLIT)AFFIMED N V COM EUR0.1 (POST REV SPLIT)AFFIMED N V COM EUR0.1 (POST REV SPLIT)

AFFIMED N V COM EUR0.1 (POST REV SPLIT)

No trades
See on Supercharts

0HL9 fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Affimed NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of cancer immunotherapies. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. It operates through the Germany and USA geographical segments. The company was founded in 2000 and is headquartered in Mannheim, Germany.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

0HL9 does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company